Insider transactions

Carl L Gordon

CIK 1282930 · last filed 2026-09-30

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$243.61M
Companies
25
Total Filings
111
Lifetime Open-Market Net
$90.64M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

AMRN price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
601 LEXINGTON AVENUE
54TH FLOOR
NEW YORK, NY 10022
Related Filers
Erez Chimovits — 3 joint filings, latest 2024-05-20
OrbiMed Israel BioFund GP Limited Partnership — 3 joint filings, latest 2024-05-20
OrbiMed Israel GP Ltd. — 3 joint filings, latest 2024-05-20
Pacira BioSciences, Inc. — 2 joint filings, latest 2011-02-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ADRX Director 8,974,061 — — $16.15M 1 2026-09-30
ETRA Director 2,002,310 — — $20.00M 1 2026-09-23
BlossomHill Therapeutics, Inc. (BLSM) Delisted Director 2,089,279 $16.18 $33.79M $10.00M 2 2026-08-12
SCTX Director 348,825 $16.19 $5.65M $15.00M 2 2026-07-29
CMPX Director 15,219,994 $0.77 $11.71M $14.98M 10 2026-01-05
KROS Director 764,405 $11.59 $8.86M -$5.00M 8 2025-12-18
MBX Director 747,887 $52.14 $38.99M $14.02M 3 2025-02-19
NCNA Director — $1.07 — $0 1 2024-08-23
Terns Pharmaceuticals, Inc. (TERN) Delisted Director 1,968,480 $52.95 $104.23M $17.44M 9 2024-07-17
ACET Director 41,154 $3.92 $161.3K $9.33M 10 2024-06-07
Theseus Pharmaceuticals, Inc. (THRX) Delisted Director 0 $4.06 $0 $14.49M 9 2024-02-14
AVBP Director 1,513,664 $15.61 $23.63M $8.00M 1 2024-01-31
Kinnate Biopharma Inc. (KNTE) Delisted Director 1,368,339 $2.65 $3.63M $24.75M 9 2023-06-13
Disc Medicine, Inc. (GMTX) Delisted Director — $13.50 — $0 1 2021-10-06
ORIC Director 2,212,571 $9.09 $20.11M -$10.67M 8 2021-06-17
Prevail Therapeutics Inc. (PRVL) Delisted Director 13,822,463 — — $15.00M 2 2020-06-19
Turning Point Therapeutics, Inc. (TPTX) Delisted Director 2,027,550 $76.01 $154.11M $6.48M 2 2020-06-17
ALEC Director 94,075 $1.95 $183.3K $7.82M 2 2019-05-14
ARMO BioSciences, Inc. (ARMO) Delisted Director 0 — — $0 3 2018-06-22
X4 Pharmaceuticals, Inc (ASNS) Delisted Director 3,115 $0.08 $243 $5.00M 4 2018-06-07
NTLA Director 2,662,180 $11.78 $31.36M $4.50M 3 2017-05-19
Cartesian Therapeutics, Inc. (SELB) Delisted Director 12,193 $0.88 $10.7K $7.70M 1 2016-06-29
AMRN Director 285 $12.00 $3.4K -$108.10M 13 2012-09-05
PCRX Director 2,828,941 $36.39 $102.95M $3.75M 1 2011-02-10
GNOM Director — $68.00 — $0 1 2010-12-02

Recent Filings · Page 8 of 12

111 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-01-26 — Mixed −13,822,463 $0
2020-12-09 Kinnate Biopharma Inc. (KNTE) Delisted Conv (C) +3,097,929 $0 EDGAR
2020-12-04 Kinnate Biopharma Inc. (KNTE) Delisted Buy (P) +750,000 $15.00M EDGAR
2020-12-04 Kinnate Biopharma Inc. (KNTE) Delisted Grant (A) — $0 EDGAR
2020-09-17 ACET Grant (A) +6,018,452 $0 EDGAR
2020-06-23 — Buy (P) +1,455,132 $7.28M
2020-06-19 Prevail Therapeutics Inc. (PRVL) Delisted Grant (A) — $0 EDGAR
2020-06-17 Turning Point Therapeutics, Inc. (TPTX) Delisted Grant (A) — $0 EDGAR
2020-04-28 ORIC Mixed +2,765,717 $4.50M EDGAR
2020-04-27 ORIC Grant (A) — $0 EDGAR
Showing 71–80 of 111
Page 8 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.